Alto Neuroscience’s (ANRO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alto Neuroscience (NYSE:ANRO) in a report released on Thursday,Benzinga reports. The firm currently has a $50.00 price target on the stock.

A number of other research analysts have also recently weighed in on ANRO. Jefferies Financial Group reissued a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. BTIG Research boosted their price target on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Chardan Capital restated a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Thursday. Finally, Wedbush decreased their price objective on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating on the stock in a research note on Thursday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Price Performance

Shares of ANRO opened at $21.57 on Thursday. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $25.17. The firm has a 50-day simple moving average of $19.27 and a 200-day simple moving average of $14.88. The company has a debt-to-equity ratio of 0.12, a quick ratio of 15.69 and a current ratio of 15.69. The company has a market capitalization of $688.95 million, a price-to-earnings ratio of -9.89 and a beta of 2.01.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.11. On average, equities research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Torren Management LLC purchased a new position in Alto Neuroscience during the fourth quarter worth about $62,000. Balyasny Asset Management L.P. acquired a new position in shares of Alto Neuroscience during the 4th quarter valued at about $198,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Alto Neuroscience during the 4th quarter valued at about $221,000. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of Alto Neuroscience by 13.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after acquiring an additional 2,055 shares during the period. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Alto Neuroscience during the 4th quarter worth about $304,000.

More Alto Neuroscience News

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Several brokers reaffirmed buy/outperform views and high upside potential — HC Wainwright kept a Buy and a $50 price target (large upside vs. current price). Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy with a $30 target, signaling continued analyst conviction despite the trial miss. Article Title
• Positive Sentiment: JonesTrading kept a Buy rating while trimming its target from $49 to $44 — still implying substantial upside from current levels. Article Title
• Positive Sentiment: Robert W. Baird cut its target to $38 but left an Outperform rating — another signal that some analysts view the selloff as a buying opportunity. Article Title
• Neutral Sentiment: Wedbush trimmed its target to $21 and moved to a Neutral rating, reflecting a more cautious stance but only a small target cut vs. price. Article Title
• Neutral Sentiment: Company fundamentals: recent quarter slightly beat EPS expectations, Alto has a market cap near $689M, high liquidity metrics (current/quick ratio ~15.7) and high beta (~2.0) — factors that increase volatility but limit near-term solvency concerns.
• Negative Sentiment: Trial failure: Alto’s schizophrenia study missed its primary endpoint; that clinical setback is the primary driver of selling pressure and re-pricing. Article Title
• Negative Sentiment: Market reaction/coverage: multiple headlines highlight a sharp drop and pre-market weakness after the study news, amplifying volatility and headline-driven flows. Article Title
• Negative Sentiment: Sentiment hit from coverage calling the result a “shocking miss,” which can accelerate short-term selling and make recovery dependent on management commentary, further data, or new catalysts. Article Title

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.